Xavier Montalban


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Xavier Montalban is an internationally recognized neurologist who is considered a key opinion leader within the field of multiple sclerosis (MS). Dr. Montalban has held diverse leadership positions and is currently a Professor of Medicine and Director of the Neurology Department at the University of Toronto. He also serves as Chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, Spain. The Multiple Sclerosis Centre of Catalonia, or Cemcat, is accredited as a national flagship service for the MS care process within the context of the Flagship Centres, Units, and Services programme of the Spanish Ministry of Health. Dr. Montalban is a former president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and recently co-directed the development of the first Multiple Sclerosis Treatment Guidelines for ECTRIMS and the European Academy of Neurology. He has contributed more than 500 publications and several book chapters to the academic arena, served on multiple steering committees of clinical trials related to multiple sclerosis, and is a valued member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials. With more than 25 years of research, Dr. Montalban continues to strive to discover more effective therapies for patients with MS and has brought paradigm shifts to the way we understand and treat MS.

Recent Publications

  1. Cook, S, Leist, T, Comi, G, Montalban, X, Giovannoni, G, Nolting, A et al.. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord. 2019;29 :157-167. doi: 10.1016/j.msard.2018.11.021. PubMed PMID:30885374 .
  2. Pareto, D, Sastre-Garriga, J, Alberich, M, Auger, C, Tintoré, M, Montalban, X et al.. Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology. 2019; :. doi: 10.1007/s00234-019-02191-3. PubMed PMID:30834955 .
  3. Zuluaga, MI, Otero-Romero, S, Rovira, A, Perez-Hoyos, S, Arrambide, G, Negrotto, L et al.. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019; :. doi: 10.1212/WNL.0000000000007178. PubMed PMID:30824557 .
  4. Turner, B, Cree, BAC, Kappos, L, Montalban, X, Papeix, C, Wolinsky, JS et al.. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J. Neurol. 2019; :. doi: 10.1007/s00415-019-09248-6. PubMed PMID:30820738 .
  5. Ciccarelli, O, Cohen, JA, Reingold, SC, Weinshenker, BG, International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18 (2):185-197. doi: 10.1016/S1474-4422(18)30460-5. PubMed PMID:30663608 .
  6. Pappolla, A, Midaglia, L, Boix Rodríguez, CP, Puig, AA, Lung, M, Camps, IR et al.. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2019;92 (6):296-298. doi: 10.1212/WNL.0000000000006801. PubMed PMID:30587519 PubMed Central PMC6382059.
  7. Gasperini, C, Prosperini, L, Tintoré, M, Sormani, MP, Filippi, M, Rio, J et al.. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2019;92 (4):180-192. doi: 10.1212/WNL.0000000000006810. PubMed PMID:30587516 PubMed Central PMC6345120.
  8. Costa, C, Eixarch, H, Martínez-Sáez, E, Calvo-Barreiro, L, Calucho, M, Castro, Z et al.. Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions. Am. J. Pathol. 2019;189 (3):665-676. doi: 10.1016/j.ajpath.2018.11.007. PubMed PMID:30553833 .
  9. Amezcua, L, Beecham, AH, Delgado, SR, Chinea, A, Burnett, M, Manrique, CP et al.. Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. Ann Clin Transl Neurol. 2018;5 (11):1362-1371. doi: 10.1002/acn3.646. PubMed PMID:30480030 PubMed Central PMC6243381.
  10. Jensen, PEH, Warnke, C, Ingenhoven, K, Piccoli, L, Gasis, M, Hermanrud, C et al.. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. J. Neuroimmunol. 2019;326 :19-27. doi: 10.1016/j.jneuroim.2018.11.002. PubMed PMID:30447419 .
Search PubMed

Affiliations & Other Activities

  • The Waugh Family Chair in Multiple Sclerosis Research, St. Michael’s Hospital
  • Medical Director, the BARLO MS Centre, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Division Director, Department of Neurology, University of Toronto
  • Director, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)